Marianne van der Steen
Marianne van der Steen is Professor at the Faculty of Health, Medicine and Life Sciences, Maastricht University (MERLN). Since 2006, she has been involved as consultant, business developer and coach in life sciences start-ups in the Netherlands and Belgium. Marianne is the director of RegMed XB, a regenerative medicine translational institute focused on the development of patient solutions and start-ups.
Chrétien holds a PhD in OptoElectronics from Delft University. He founded ThreeFive Photonics. For the past 10 years he has shared his entrepreneural experiences in coaching cleantech and life sciences startups and scale-ups. Additionally, he founded the lifesciences@work accelerator, which is currently part of Health-Holland.
Haifen Hu holds a MSc in Biotechnology from Wageningen University. She is the founder and director of Hyphen Projects. For the past 13 years she has set up and organised conferences, events, summer schools and courses for the Life Sciences & Health sector. Before she worked as Project Manager and Manager Entrepreneurship & Education for BioPartner Network.
Operational Program Manager
Remco Jongkind holds a MSc in Pharmacology from the University of Oxford. As Program Manager Education at Hyphen Projects he is amongst others responsible for the trainings and courses offered by Hyphen Projects. Previously he has done research and teaching at the Amsterdam Medical Centre and the University of Oxford.
EY is a global leader in advisory, assurance, tax, and transaction services. At EY, we are committed to building a better working world — with increased trust and confidence in business, sustainable growth, development of talent in all its forms, and greater collaboration. The insights and quality services we deliver help build trust and confidence in the capital markets and in economies the world over.
About EY’s Global Life Sciences Sector
Life sciences companies — from emerging start-ups to multinational enterprises — face new challenges in a rapidly changing health care ecosystem. Payers and regulators are increasing scrutiny and accelerating the transition to value and outcomes. Big data and patient-empowering technologies are driving new approaches and enabling transparency and consumerism. Players from other sectors are entering health care, making collaborations increasingly complex. These trends challenge every aspect of the life sciences business model, from R&D to marketing.
Our Global Life Sciences Sector brings together a worldwide network — more than 22,000 sector-focused advisory, assurance, tax, and transaction professionals — to anticipate trends, identify their implications and develop points of view on responding to critical issues. We help our clients in navigating their way forward and achieve concrete successes in the new ecosystem.
For our latest insights, please visit www.ey.com/vitalsigns
Frank van de Manakker:
Frank van de Manakker works at EY as business development leader and industry specialist in the Life Sciences industry sector for Western Europe & Maghreb. In this role, Frank initiates and performs activities that help pharmaceutical and medical companies realizing sustainable growth, improved revenues, higher efficiencies and profitability, and/or lower risks and costs. By applying his (technical) life sciences background and business understanding, having regular contacts with clients and other industry stakeholders, and by operating in multidisciplinary teams of EY experts, he aims to identify the most relevant and customized solutions to key (industry specific) business issues for EY’s life sciences clients.
Frank has a PhD in Pharmaceutics of Utrecht University and a MSc in Pharmaceutical Sciences of VU University Amsterdam. With his background in the field of pharmaceutical and medical R&D and product development, Frank offers over 10 years of experience in working with and for large, mid-sized, and start-up biotech, medtech and pharma companies, including Pfizer, Dr. Reddy’s (former Octoplus), DSM, Teva Pharmaceuticals, Boston Scientific, MSD, Merus, InGell Labs, and others.